Celecoxib
Brand names: Celebrex
Celecoxib is a selective COX-2 inhibitor non-steroidal anti-inflammatory drug used for pain and inflammation in osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute postoperative pain.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively inhibits the COX-2 enzyme, reducing prostaglandin-mediated inflammation and pain while largely sparing COX-1.
Prescribing in practice
- Like other NSAIDs it carries cardiovascular thrombotic risk, so it should be used at the lowest effective dose for the shortest duration and avoided in established ischaemic heart disease, cerebrovascular or peripheral arterial disease, and significant heart failure.
- It is contraindicated in patients with sulfonamide hypersensitivity and in those who have had asthma, urticaria, or allergic reactions to aspirin or other NSAIDs.
- Although COX-2 selectivity reduces gastrointestinal injury, ulceration and bleeding can still occur, and renal function and blood pressure may be adversely affected.
Monitoring
Monitor blood pressure, renal function, and for gastrointestinal or cardiovascular adverse effects, particularly with prolonged use or in at-risk patients.
Counselling the patient
- Take it with food and use the lowest dose that controls your symptoms.
- Report any indigestion, black stools, or signs of bleeding.
- Seek urgent help for chest pain, breathlessness, or sudden weakness.
Evidence & guidelines
Celecoxib's analgesic and anti-inflammatory efficacy is supported by trials, with cardiovascular and gastrointestinal safety considerations reflected in MHRA advice.
Reference: Celebrex SPC; MHRA Drug Safety Update 2013; PROSPECT Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- ASA Physical Status Classification · Pre-operative Risk
- Numeric Rating Scale (NRS) for Pain · Pain Assessment
- POSSUM Score for Surgical Morbidity and Mortality · Perioperative Risk
- SORT (Surgical Outcome Risk Tool) · Perioperative Risk
- Revised Cardiac Risk Index (RCRI / Lee Index) · Perioperative Risk
- ASA Physical Status Classification · Perioperative Risk
- Major Trauma — Primary Survey (ATLS) · ATLS 10th Edition; JRCALC; NICE NG39
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Burns — TBSA Estimation & Fluid Resuscitation · British Burn Association; EMSB; RCEM 2024
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Hypertrophic Pyloric Stenosis · BAPS / RCPCH